Tyson Foods Announces First Quarter Earnings Conference Call and Webcast

Written by Customer Service on January 10, 2022. Posted in Public Companies.

SPRINGDALE, Ark., Jan. 10, 2022 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN) will release first quarter 2022 financial results on Monday, February 7, 2022. Management will host a conference call and webcast beginning at 9:00 a.m. Eastern Time (8:00 a.m. Central Time). A press release and supplemental materials will be issued before the market opens that morning. WebcastA link for the webcast of the conference call is available on the Tyson Investor Relations website at http://ir.tyson.com. The webcast can also be accessed by the following direct link: https://event.on24.com/wcc/r/3578688/776A66724A330AB0D97CEC70248EB449. Audio OnlyParticipants may join the audio only version of the conference call by calling: Dial In (Toll Free): 1-844-890-1795International Dial In: 1-412-717-9589 Please note: All dial-in participants should...

MARKSMEN ANNOUNCES FILING OF EARLY WARNING REPORT BY GLENN WALSH

Written by Customer Service on January 10, 2022. Posted in Public Companies.

CALGARY, ALBERTA, Jan. 10, 2022 (GLOBE NEWSWIRE) — Marksmen Energy Inc. (“Marksmen” or the “Company”) announces that an early warning report has been filed by Glenn Walsh, an insider of the Company. On December 30, 2021, Mr. Walsh exercised 800,000 share purchase warrants of the Issuer (the “Warrants”) held indirectly through his wholly owned company, Conex Services Inc. (“Conex”), resulting in the disposition of 800,000 Warrants and the acquisition of 800,000 common shares of the Company (the “Common Shares”). Mr. Walsh previously filed an early warning report on May 9, 2016, and the exercise of the Warrants, combined with an increase in the issued and outstanding securities of the Company, resulted in a decrease to his diluted holdings of 3.80% which triggered the requirement to file the report. As at the date of Mr. Walsh’s...

Infant Bacterial Therapeutics today announces that new patent protection is granted in Australia

Written by Customer Service on January 10, 2022. Posted in Public Companies.

Infant Bacterial Therapeutics AB (IBT) today announces that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBP-9414 is currently in Phase III development for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in preterm infants. The ambition for IBP-9414 is to become the world’s first approved pharmaceutical grade probiotic drug to prevent life threatening infant diseases including NEC, by promoting healthy stomach- and bowel development in premature infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are pending in additional important future markets including the US and Europe. This patent further increases...

Virtu Financial Issues Warning Regarding Fraudulent Cryptocurrency Scams

Written by Customer Service on January 10, 2022. Posted in Public Companies.

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ:VIRT) is issuing a warning to the public to be alert for cryptocurrency scams, fraudulent offers, and fraudulent communications by individuals purporting to be affiliated with Virtu. Please note that Virtu and its subsidiaries do not open accounts for individual investors to trade cryptocurrencies, securities, futures or commodities and do not accept money from individual investors in connection with any type of trading account. If you have been contacted by any person(s) purporting to be acting on behalf of or in connection with Virtu to trade cryptocurrency, be aware that these individuals are not authorized representatives of Virtu. If you believe you have been the victim of a fraud, contact your local FBI office via its Internet Crime Complaint Center...

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

Written by Customer Service on January 10, 2022. Posted in Public Companies.

Agreement combines IASO Bio and Innovent’s CAR construct, validated in clinical trials, with Sana’s in vivo and ex vivo engineered cell therapy programs SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics (“IASO Bio”), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines, and Innovent Biologics (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today jointly announced that the companies...

Mercer International Inc. to Present at Upcoming 25th Annual CIBC Western Institutional Investor Conference

Written by Customer Service on January 10, 2022. Posted in Public Companies.

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) — Mercer International Inc. (Nasdaq: MERC) today announced that David M. Gandossi, President and CEO, will be presenting at the following upcoming conference: 25th Annual CIBC Western Institutional Investor Conference Thursday, January 20th, 2022 Presentation at 2:35 PM PST A copy of the presentation will be posted in the “Investors – News Releases & Presentations” section on the Company’s web site (https://mercerint.com/investors/news-releases-presentations/) on the morning of the event. At Mercer International Inc., we are exceptional people creating bioproducts for a more sustainable world. We are a diversified global producer of forest products, bioproducts, and green electricity with operations in Germany, Canada, the United States, and Australia with a consolidated annual...

Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue

Written by Customer Service on January 10, 2022. Posted in Earnings Releases And Operating Results.

IRVINE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue. Preliminary Fourth Quarter Highlights: Preliminary unaudited revenue is expected to be between $82.8 and $83.3 million for the fourth quarter of 2021, up 14% sequentially and 71% year-over-year (at the midpoint of the range). Preliminary unaudited revenue for the full year 2021 is expected to be between $276.6 and $277.1 million, up approximately 98% over the full year 2020. Treated 7,700 patients, an increase of 1,000 procedures or 15% from 6,700 procedures completed in Q3. Over 90% of overall procedures and sequential procedural growth...

WashREIT to Release Fourth Quarter 2021 Results on Thursday, February 17th

Written by Customer Service on January 10, 2022. Posted in Public Companies.

WASHINGTON, Jan. 10, 2022 (GLOBE NEWSWIRE) — WashREIT (NYSE:WRE) will release fourth quarter earnings results after market close on Thursday, February 17, 2022. The conference call will be held on Friday, February 18, 2022, at 11:00 am ET. Conference call access information is as follows: USA Toll Free Number: 888-506-0062 International Toll Number: 973-528-0011 Entry Code 484083 Instant replay of the conference call will be available until Friday, March 4, 2022, at 12:00 am ET. Instant replay access information is as follows: USA Toll Free Number: 877-481-4010 International Toll Number: 919-882-2331 Conference ID: 44242 The live webcast of the conference call will be available on the investor section of WashREIT’s website at www.washreit.com. WashREIT owns approximately...

<div>Fortress Transportation and Infrastructure Investors LLC to Participate in the Cowen 43rd Annual Aerospace/Defense & Industrials Virtual Conference</div>

Fortress Transportation and Infrastructure Investors LLC to Participate in the Cowen 43rd Annual Aerospace/Defense & Industrials Virtual Conference

Written by Customer Service on January 10, 2022. Posted in Public Companies.

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) — Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) (the “Company”) today announced that Joe Adams, FTAI Chief Executive Officer, will present virtually at the Cowen 43rd Annual Aerospace/Defense & Industrials Conference at 12:40 PM (ET) on Wednesday, February 9, 2022. Interested investors may access the Company’s presentation materials posted in the Investor Relations section of the Company’s website, www.ftandi.com. About Fortress Transportation and Infrastructure Investors LLC Fortress Transportation and Infrastructure Investors LLC owns and acquires high quality infrastructure and equipment that is essential for the transportation of goods and people globally. FTAI targets assets that, on a combined basis, generate strong and stable cash flows with the potential...

December AMK Report

Written by Customer Service on January 10, 2022. Posted in Public Companies.

CONCORD, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) — AssetMark Financial Holdings, Inc. (NYSE: AMK) released its “AssetMark Monthly Knowledge” Report today. In addition, the Company also disclosed its AMK Report – Annual Summary, which can be found by clicking here. Company highlights for the month of December 2021 include: Platform assets of $93.5 billion at the end of December, up 25.5% year-over-year. Net flows were $1.1 billion in the month of December, up 67.0% year-over-year. AssetMark Trust Company client cash was $2.93 billion, up 11.8% year-over-year. Number of households increased 12.5% year-over-year to 209,900 at the end of December. Change Mo. Yr. Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 PLATFORM...

Day: January 10, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice